Synonyms: (R)-lisophylline | CT-1501R
Compound class:
Synthetic organic
Comment: Lisophylline is an active metabolite of pentoxifylline. The compound has novel anti-inflammatory properties, likely through inhibition of IL-12 signalling and STAT-4 activation [2]. It is reported to prevent type 1 diabetes in preclinical models [3] and improve the function and viability of isolated or transplanted pancreatic islets [1]. Evidence suggests that combined treatment with lisofylline (for its anti-inflammatory action) and exendin-4 (to enhance beta-cell proliferation) can reverse autoimmune diabetes in the non-obese diabetic (NOD) mouse model [4].
|
|
No information available. |
Summary of Clinical Use ![]() |
A Phase 1/2 clinical trial in patients with type I diabetes mellitus (NCT01603121) was terminated as it was unable to enroll sufficient numbers of subjects. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01603121 | Lisofylline as Continuous Subcutaneous and Intravenous Administration in Subjects With Type 1 Diabetes Mellitus | Phase 1/Phase 2 Interventional | Eastern Virginia Medical School |